Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Legal Resolution Overview

On December 15, 2015, Pacira announced an amicable resolution with the United States in connection with its lawsuit filed on September 8, 2015, Pacira Pharmaceuticals, Inc. et al v. United States Food & Drug Administration et al, 15-cv-07055 (SDNY Sept. 8, 2015)(LAK).  The resolution confirms that EXPAREL (bupivacaine liposome injectable suspension) is, and since 2011 has been, broadly indicated for administration into the surgical site to provide postsurgical analgesia.
Press Release
Executive Summary
Presentation: FDA Resolution Overview

Legal Resolution Documents

The resolution resulted in an approved labeling supplement which clarified and revised the EXPAREL package insert, a settlement agreement articulating the legal terms of the resolution and a letter from Dr. Janet Woodcock, Director of the FDA Center for Drug Evaluation and Research (CDER), formally rescinding the September 2014 Warning Letter. The pertinent documents are available below.

Rescission of Warning Letter
Settlement Agreement
Prescribing Information (Revised December 14, 2015)

Declarations Supporting Approved EXPAREL Label

Click to Expand
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com